Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gyre TherapeuticsGYRE +0.33%39 EV-to-EBIT is 279.21 as of Aug. 05, 2026, which is 278% above its 10-year median of 73.81. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.77 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 381 Biotechnology companies, Gyre Therapeutics ranks worse than 97.64% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Gyre Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $623.3 Mil.
Gyre Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics EV-to-EBIT Related Terms
Gyre Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gyre Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's EV-to-EBIT falls into.
Gyre Therapeutics's current Enterprise Value is $674.6 Mil.
Gyre Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (GYRE) has a EV-to-EBIT of 279.21 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Gyre Therapeutics and its competitors. This is 278% above median its historical median of 73.81. Over the past decade, Gyre Therapeutics' EV-to-EBIT has ranged from 20.27 to 300.74. According to the industry distribution chart, Gyre Therapeutics ranks #372 out of 381 companies in the Biotechnology industry, placing it in the top 97.6%.
Is Gyre Therapeutics' EV-to-EBIT too high?
Gyre Therapeutics' current EV-to-EBIT of 279.21 is 278% above median its 10-year median of 73.81. Over the past 10 years, this metric has ranged from a low of 20.27 to a high of 300.74. The Biotechnology industry median EV-to-EBIT is 13.65. Gyre Therapeutics' value of 279.21 is 1945.5% above this industry median. Based on the distribution chart, Gyre Therapeutics ranks #372 out of 381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' EV-to-EBIT compare to OCS and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #372 out of 381 companies for EV-to-EBIT. This places Gyre Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 13.65. Gyre Therapeutics' value of 279.21 is 1945.5% above this benchmark. Historically, Gyre Therapeutics' own EV-to-EBIT has ranged from 20.27 to 300.74 over the past decade. While the company's 10-year median is 73.81 vs. the industry median of 13.65, Gyre Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.65, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current EV-to-EBIT of 279.21 is 1945.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Gyre Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current EV-to-EBIT is 279.21, which is 278% above median its own 10-year median of 73.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.77, compared to a current price of $6.17 — trading 36.8% below its estimated fair value. The current EV-to-EBIT is 279.21, which is 278% above median its 10-year median of 73.81 and 1945.5% above the Biotechnology industry median of 13.65. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current EV-to-EBIT is 279.21 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.17 is trading 36.8% below its estimated GF Value™ of $9.77.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
EV-to-EBIT: 279.21 (278% above median its 10-year median of 73.81)
GF Value™: $9.77 vs. price of $6.17 (36.8% below fair value)
Industry Position: 1945.5% above the Biotechnology median (#372 of 381)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
